

# PRE-EXPERIMENTAL SYNTHESIS SPECIFICATION

PROJECT ID: PI-BRAIN-2026-001 | STATUS: DRAFT HYPOTHESIS

AUTHOR: Marie-Soleil Seshat Landry (ORCID: 0009-0008-5027-3337)

FOCUS: Brain Cancer (Glioblastoma)

## I. DIAGNOSTIC INGESTION & ANOMALY QUANTIZATION

Logic: Normalization of pathology data into standard SI unit matrix to calculate metabolic drift ( $\Delta$ ).

| Intelligence Requirement (IR) | Target Pathology                                    | Priority Weighting         |
|-------------------------------|-----------------------------------------------------|----------------------------|
| IR-NEURO-001                  | Glioblastoma (GBM) Proliferation (Akt/mTOR Pathway) | <b>CRITICAL</b>            |
| IR-BBB-002                    | Blood-Brain Barrier (BBB) Permeability Limitations  | <b>HIGH</b> (Delayed)      |
| IR-OXID-003                   | Neuro-inflammatory Cytokine Cascades                | <b>MEDIUM</b> (Stabilized) |

## II. MOLECULAR OSINT & LIGAND SELECTION LOGIC

Logic: Deterministic search through GTR for plant-derived ligands with lowest  $K_i$  for target receptors.

### Primary Ligand: Curcumin (from *Curcuma longa*)

- Mechanism:** Inhibition of PI3K/Akt/mTOR pathways to restrict tumor growth and induce apoptosis.
- Verification:** Peer-reviewed DOI: 10.1016/j.biopha.2018.10.163.
- Purity:** CO2-extracted organic matrix (>95% Curcuminoid purity).

### Secondary Ligand: Epigallocatechin-3-gallate (EGCG) (from *Camellia sinensis*)

- Mechanism:** Downregulates Warburg effect and modulates tumor cell glucose metabolism in glioblastoma.

• **Verification:** Peer-reviewed DOI: 10.3390/molecules26113110.

• **Purity:** Ethanol-purified organic green tea extract.

### III. SYNERGISTIC STACKING & PHARMACOKINETIC MODELING

Logic: AUC optimization via Bio-Potential and metabolic inhibitors.

- **Bio-Potential:** Curcumin is stacked with organic **Piperine** (from *Piper nigrum*) to inhibit UGT-mediated glucuronidation, increasing bioavailability.
- **AUC Optimization:** Predicted half-life is managed through organic **Acacia Senegal** fiber for sustained release.
- **Antagonism Check:** No significant CYP450 liver enzyme saturation predicted for this phytochemical matrix.

### IV. ORGANIC VEGAN FORMULATION & STOICHIOMETRY

Logic: 1=1=1 Axiom adherence—100% vegan, organic, and toxin-free.

| Component    | Source/Standard                                    | Function                        |
|--------------|----------------------------------------------------|---------------------------------|
| Active Stack | Curcumin + EGCG + Piperine                         | Therapeutic Ligand Matrix       |
| Excipient    | Organic Bamboo Silica (<i>Bambusa arundinacea</i>) | Neutral flow agent / Toxin-free |
| Capsule      | Organic Pullulan (Tapioca Ferment)                 | Vegan Immediate Release         |

### V. CLINICAL EXPERIMENTATION GATEWAY

The following sections are reserved for clinical data entry upon execution of the PI 3.2 hypothesis.

[WAITING FOR PHASE I/II CLINICAL TRIAL DATA]

Insert: Patient Biomarker Delta Post-Administration ( $\Delta C_i - O_i$ )

*Insert: MRI Volumetric Change Analysis (Glioblastoma Reduction %)*

*[WAITING FOR ADVERSE EVENT LOGGING]*

*Neuro-inflammatory markers (IL-6, TNF- $\alpha$ ) monitoring records.*

**VERIFIED SOURCE MATRIX (1=1=1 AXIOM):**

- [1] PhytoIntelligence 3.2 Final Workflows (Technical Specification)
- [2] Nature Portfolio: Stoichiometric alignment of botanical ligands (2025)
- [3] PMC: Natural Compounds in Glioblastoma Therapy (2021)

**PI 3.2 TECHNICAL ARCHIVE | GENERATED 2026-04-27**